TRIUMPH-1 trial results

Adults without diabetes who had obesity or overweight with a weight-related condition.

Retatrutide

Phase: Phase 3
Follow-up: 80 weeks
Randomised: 2,339
Sponsor: Eli Lilly
Publication: New England Journal of Medicine · 2026

Randomised, double-blind, placebo-controlled. Treatment-regimen estimand. The paper reports 2,339 randomised participants and the registry lists 2,335 enrolled.

Mean body weight change at 80 weeks

Retatrutide 4 mg−17.6%
Retatrutide 9 mg−23.7%
Retatrutide 12 mg−25.0%
Placebo−3.9%

Mean body weight change at 80 weeks
Trial arm	Result
Retatrutide 4 mg	−17.6%
Retatrutide 9 mg	−23.7%
Retatrutide 12 mg	−25.0%
Placebo	−3.9%

Safety. The publication reports gastrointestinal adverse events as the most common.

Published paper PubMed abstract NCT05929066